EMINEM: Efficacy of Muscoril In NEck Myofascial Syndromes

This study has been completed.
Sponsor:
Information provided by:
Sanofi
ClinicalTrials.gov Identifier:
NCT00272532
First received: January 4, 2006
Last updated: February 18, 2008
Last verified: February 2008
  Purpose

Study objective:

  • To demonstrate, in patients with myofascial pain syndrome in cervical region, the degree of efficacy of thiocolchicoside ointment administered to trigger point regions compared with the trigger point injection.

Condition Intervention Phase
Myofascial Pain Syndromes
Drug: Thiocolchicoside
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind
Primary Purpose: Treatment
Official Title: The Efficacy of Topical Thiocolchicoside in Cervical Myofascial Pain Syndrome: Triple-Arm, Single-Blind, Randomized, Prospective, Phase IV Clinical Study

Resource links provided by NLM:


Further study details as provided by Sanofi:

Primary Outcome Measures:
  • Pain relief (Visual Analog Scale and sensitometer) and increase in mobility of neck. Patient and physician satisfaction

Estimated Enrollment: 65
Study Start Date: April 2005
  Eligibility

Ages Eligible for Study:   18 Years to 50 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Submitted to clinic with a complaint of head and neck pain
  • Be diagnosed as having myofascial pain syndrome by determining the active trigger points in trapezius and/or interscapular region according to criteria of Simons and Travel
  • Have 1 to 8 active trigger point(s)

Exclusion Criteria:

  • Have evident cervical discopathy and signs of osteoarthritis
  • Have bleeding diathesis or using anticoagulant medication which hinders injection
  • Have known malignity, being used steroids, have immunodepressive disorders and/or being taken immunodepressive drugs
  • Be pregnant or have the possibility of being pregnant or not being used a regular contraceptive method
  • Have known allergic reaction against Thiocolchicoside
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00272532

Locations
Turkey
Sanofi-Aventis
Istanbul, Turkey
Sponsors and Collaborators
Sanofi
Investigators
Study Director: Edibe Taylan Sanofi
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00272532     History of Changes
Other Study ID Numbers: L_9892
Study First Received: January 4, 2006
Last Updated: February 18, 2008
Health Authority: Turkey: Ministry of Health

Additional relevant MeSH terms:
Myofascial Pain Syndromes
Fibromyalgia
Somatoform Disorders
Muscular Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Neuromuscular Diseases
Nervous System Diseases
Mental Disorders
Colchicine
Gout Suppressants
Antirheumatic Agents
Therapeutic Uses
Pharmacologic Actions
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents

ClinicalTrials.gov processed this record on July 31, 2014